Lisata Therapeutics: Advancing Precision Oncology at J.P. Morgan Healthcare Conference 2026

### Advancing Precision Oncology: IDEAYA Biosciences at the Forefront of Cancer Treatment Innovations

IDEAYA Biosciences, Inc. participates in the upcoming 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The presentation, led by CEO Yujiro S. Hata, underscores the company's commitment to precision medicine in oncology. With a focus on innovative cancer therapies, IDEAYA aims to address the urgent needs of patients with specific genetic profiles driving their cancer. By combining small-molecule drug discovery, structural biology, and bioinformatics, IDEAYA adopts an integrated approach that seeks to develop targeted therapies that are more effective and selective compared to traditional treatments.

The company’s robust pipeline includes initiatives centered on synthetic lethality and antibody-drug conjugates (ADCs), which are designed for specific solid tumor indications. This strategic focus aims to create first-in-class therapies that align closely with the genetic drivers of cancer, potentially leading to improved clinical outcomes for patients. IDEAYA is not only committed to advancing its therapeutic offerings but is also dedicated to validating translational biomarkers that can guide treatment decisions, thus enhancing the precision of oncological care.

As IDEAYA prepares to showcase its innovations at the J.P. Morgan conference, the company emphasizes its dedication to keeping stakeholders updated about significant developments in line with SEC filing requirements. The inclusion of a Q&A session following the presentation allows for direct engagement with investors and industry experts, reinforcing IDEAYA's transparent approach in communicating its advancements in cancer research and therapy development. This participation reflects IDEAYA's ongoing mission to lead in the field of precision oncology, aiming for breakthroughs that can transform treatment paradigms for cancer patients worldwide.

### Other Relevant Developments in Oncology

BridGene Biosciences, Inc. recently appointed Nobel Prize-winning immunologist Dr. Bruce A. Beutler to its Scientific Advisory Board. This strategic addition is expected to bolster BridGene's capabilities in drug development programs targeting oncology and immunology. Dr. Beutler’s expertise will guide the company in navigating complex translational data and developing treatments for autoimmune and inflammatory diseases.

In a separate development, Neurocrine Biosciences, Inc. is also set to present at the J.P. Morgan Healthcare Conference, highlighting its diverse portfolio of FDA-approved therapies and ongoing clinical development efforts. The company focuses on addressing neurological and neuropsychiatric disorders, showcasing its commitment to innovative treatment solutions that aim to improve patient outcomes in complex conditions.